Novartis sold 62 million courses of its malaria drug, Coartem, at cost to poor African countries.

FORBES: Magazine Article

Called Coartem, it combines a derivative of artemisinin, an extract from sweet wormwood bush, with a second drug, lumefantrine.

FORBES: Fighting Malaria

Novartis (nyse: NVS - news - people ) sold 62 million courses of its malaria drug, Coartem, at cost to poor African countries.

FORBES: Issues & Ideas

But the only firm that achieved any success was Novartis, which in 1998 developed Coartem, an antimalarial drug that combines artemisinin, an extract from the sweet wormwood plant, with a compound called lumefantrine.

FORBES: Magazine Article